Durvalumab With or Without Tremelimumab vs the EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
Ann. Oncol 2022 Dec 16;[EPub Ahead of Print], A Psyrri, J Fayette, K Harrington, M Gillison, MJ Ahn, S Takahashi, J Weiss, JP Machiels, S Baxi, A Vasilyev, A Karpenko, M Dvorkin, CY Hsieh, SC Thungappa, PP Segura, I Vynnychenko, R Haddad, S Kasper, PS Mauz, V Baker, P He, B Evans, S Wildsmith, RF Olsson, A Yovine, JF Kurland, N Morsli, TY SeiwertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.